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Abstract
In recent years, there has been an increased interest in the role of glutamate, the
brain’s major excitatory neurotransmitter, in MDD. There is ample evidence that
glutamate dysfunction is present in patients with varying degrees of depression. With this
mechanistic shift behind MDD has come a better understanding of the importance of
cognitive dysfunction in depressed patients. The general view of MDD was that it was a
mood disorder, however recent evidence suggests that cognitive functioning is also
critical to relief of depressive symptomology. Attempts have been made to modulate
excitatory neural networks using a class of glutamate receptors known as ionotropic
glutamate receptors (iGlu receptors). However, drugs which act on iGlu receptors lead to
harmful exocitoxic effects and cognitive dysfunctions. Another subtype of glutamate
receptor known as metabotropic glutamate receptors (mGlu receptors) may play a more
modulatory role in excitatory neurotransmission. In the present study we investigated the
role of the mGlu 2/3 receptor subtypes in cognitive function in Long Evans rats using a
modified version of the delayed-nonmatch-to-sample task (DNMS). We made two
hypotheses, 1) that the DNMS is a working memory task, in which accuracy decreases
with increasing inter-trial intervals (ITI), 2) that antagonism of mGlu 2/3 receptors using
LY341495 would improve working memory performance on the DNMS task. In
congruence with our first hypothesis, performance on the DNMS task is decreased with
increasing ITIs. However, LY341495 administration (30 min IP) impaired DNMS
accuracy at 3 mg/kg and increased response latencies at 1 and 3 mg/kg. Therefore, it
appears that increasing neuronal glutamate is not sufficient to improve cognitive
functions such as working memory in normal subjects. Future studies may want to
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investigate the effects of LY341495 using a biological model of depression like the
chronic corticosterone model.
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Introduction
Depression, Economics, and Quality of Life Functioning
Major Depressive Disorder (MDD) is a common and severe mental disorder that
impacts more than 264 million people and is currently the leading cause of global
disability (WHO, 2017). MDD is associated with high rates of morbidity, nonremission
and reoccurrence, and an economic burden amounting to nearly $210.5 billion per year
(McIntyre et al., 2013; Muller et al., 1999; Porter, Gallagher, Thompson, & Young, 2003;
National Institute of Mental Health, 2019; American Psychiatric Association Foundation,
2019).
Despite the large number of approved pharmacotherapies, current MDD
treatments leave much to be desired. Nearly 1/3 of depressed patients find that current
antidepressants are ineffective at treating their symptoms, and the majority of the current
treatments take a significant amount of time to begin their effects (Hare & Duman.,
2020). The general view of MDD has been that it is an affective mood disorder, with
symptoms including lowered mood, loss of personal interests/relationships, and reduced
quality of life (QOL) (McIntyre et al., 2013; Porter et al., 2003). But it is also a disorder
of cognition. Recent reports suggest that MDD patients exhibit cognitive impairments in
domains such as executive functioning (working memory and attention; Diamond, 2013),
as well as psychomotor processing. Impaired patients often exhibit diminished decision
making, concentrating, and reductions in self-care tasks (e.g. dressing, grooming).
Patients with MDD generally exhibit measurable cognitive impairments that range from
1-2 standard deviations below the mean. Additionally, measures of effect sizes remain
significant ranging from 0.2-0.6 in remitted MDD patients (McIntyre et al., 2013;
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McIntyre et al., 2015a; Porter et al., 2003). Indeed, mood symptoms alone cannot account
for the entire level of disability because cognitive impairments, and functional
impairments associated with them, are still observed during mood symptom remission
(Baune et al., 2010; Shimizu et al., 2013). MDD-related cognitive impairments are also
associated with decreases in both motivation and the ability to sustain effort (Fava et al.,
2014; Scheurich et al., 2008). Patients with MDD and healthy controls exhibit similar
performance increases from motivational enhancements, but the MDD patients improve
less and remain impaired on several cognitive functions. (Jazbec, McClure, Hardin, Pine,
& Ernst, 2005; Richards & Ruff, 1989). Therefore, it appears that neither the severity of
depression nor motivation levels can account for the level of cognitive impairment seen
in MDD.
Understanding the role that cognitive dysfunction plays in MDD is important
given recent studies suggesting that losses in functional ability is a major factor in MDDassociated economic costs (McIntyre et al., 2015; Rose & Ebmeier, 2006; Shimizu et al.,
2013). While, there is little consensus what MDD features regulate QOL, mood
symptoms do not appear to be a consistent predictor. Shimizu et al. (2013) reported that
lower QOL levels are still present in patients with depressive-mood symptom remission.
Additionally, where some studies found that depressive-mood symptom treatments can
improve QOL, others found that it had little effect on QOL (Papakostas et al., 2004).
An alternative explanation for the persistence of QOL impairments may come
from the relationship between MDD and cognitive dysfunction (Jaeger, Berns, Uzelac, &
Davis-Conway, 2006). McCall & Dunn (2003) showed that poor self-evaluation scores
on measures of daily living (IADL; instrumental appraisal of daily living) are associated
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with reduced cognitive function in severely depressed patients. This idea is supported by
findings from Jaeger et al. (2006) that cognitive dysfunction severity predicts functional
recovery for patients with MDD. Further, McIntyre et al. (2015) demonstrated that
cognitive dysfunctions remain significant predictors of global disability and workplace
performance even when the depression severity was considered. Conversely, Baune et al.
(2010) found that measures of QOL like the impairments of activities of daily living
assessments (IADL/ADL) are not correlated with cognitive functioning. It is possible that
these observed differences in the role of cognitive function in QOL can be explained by
differences in age, disease state, and treatment methods of the participants. For example,
the Kiosses and Alexopoulous (2005) found evidence for reduced IADL scores in
geriatric patients with MDD, but Baune et al. (2010) did not in a sample with much wider
age ranges. Thus, although there is still no clear consensus on the symptom clusters that
drive reduced QOL scores in MDD patients, cognitive impairment may be a relevant
mediating variable.
The Impact of Depression on Cognitive Functioning
According to Roiser and Sahakian (2013) cognitive functions can be divided into
two domains consisting of hot and cold cognitive functions. Hot cognition includes
functions tied to emotionally valanced stimuli such as anhedonia, negative biases in
ruminative thoughts, recall and attention, and exaggerated reactions (McIntyre et al.,
2015; Roiser & Sahakian, 2013). Cold cognition includes information processing
functions that are not tied to emotional influences such as executive function, information
processing speed, learning and memory, and attention/concentration (McIntyre et al.,
2015; Roiser & Sahakian, 2013). It is common for patients with MDD to show impaired
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performance across a range of cold cognitive functions such as memory (short-term and
working memory), visuospatial processing, motor functioning, information processing
speed, general intelligence and decision making (Roiser & Sahakian, 2013). Interestingly
though, others have found this not to be the case, and have observed that patients with
MDD do not perform significantly different than healthy controls (Barch et al., 2003).
The inconsistency in these finding suggest that there may be issues with the
methodology, heterogeneity of the samples, or the cognitive tasks. Many of the reported
studies have failed to consider the issues of using mixed-groups, comorbid populations,
age-related differences, or inclusion of subjects with multiple treatment methods (Matsuo
et al., 2007; McIntyre et al., 2013). Thus, interpreting their collective meaning of these
study outcomes is difficult. Additionally, even fewer studies have attempted to explore
the nature of cognitive impairments prior to the onset of major depression (Marazziti,
Consoli, Picchetti, Carlini & Faravelli, 2010), which may yield valuable data about how
the disorder develops.
Overall, little attention has been paid to the effects of MDD on cognitive faculties
such as short-term and working memory. Working memory is considered to be a form of
short-term memory used to store and process complex information online for a limited
duration (Baddeley, 2001; Barch, Sheline, Csernansky, & Synder 2003). Working
memory is at best poorly understood and the literature does not suggest there is a
consensus about it or its underlying components. There are generally only a few accepted
measures of working memory for humans, and even fewer in the rodents. Further, many
of the tests used to model depression in rodents can be understood to reflect either
depressive-like behaviors or anxiety-related behaviors (Dudchenko, 2004). Additionally,
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many of the measures used in both species report inconsistent results with varying
interpretations. Many of the interpreted outcomes of these nonhuman tests make use of
anthropomorphizations of depression without fully detailing the biological substrates
underlying the observations (Chiriţă, Gheorman, Bondari, Rogoveanu, 2015; Pu et al.,
2011). These issues can create issues when trying to use these models to develop
successful treatments in humans.
History of Tasks Used to Model Depression in Humans and Rodents
When drawing comparisons between rodent and animal models, it is important to
remember that there are structural differences in the rodent PFC and that of non-human
primates and humans. In rodents, the medial prefrontal cortex (mPFC) is considered to be
the equivocal structure to the dorsolateral prefrontal cortex in humans (Liu et al., 2014).
The rodent mPFC is generally understood to include the prelimbic (PL) and infralimbic
(IL), as well as the anterior cingulate cortex (ACC). The ventral portion of the mPFC
corresponds to the subgenual cortex (Brodmann area 25) while the more dorsal mPFC is
related to the ACC in human and non-human primates. In animal models, working
memory tasks typically make use of temporal delays or variations of spatial cues, without
regard to capacity, a subtopic that is beyond the scope of this investigation. Clinical
evidence suggests that for rodent models of memory function, non-matching-to sample
tasks (NMS) are a valid method to assess working memory impairments (Davies, Molder,
Greba, & Howland, 2013; Dudchenko, 2004; Dudchenko, Wood, & Eichenbaum, 2000).
The NMS tasks as described by Dudchenko (2004) are a two trial (information/retention)
task that requires the subject to differentiate between a set of old and new stimuli in order
to receive a reward. A useful aspect of the NMS task is that it can be modified to remove
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spatial cues and to introduce temporal delays (delayed-nonmatch-to-sample, DNMS),
which allows the researcher to modify task difficulty or memory load.
The DNMS task requires the subject to remember a stimulus over a delay period
and to be able to correctly identify and select a novel stimulus from the previously
presented one when presented with both simultaneously. While it is possible to evaluate
working memory using other tasks such as the spontaneous exploration task. Measures
like the DNMS task are inversely correlated with increases in the temporal delay period,
a common hallmark of working memory function. DNMS tasks also give researchers the
advantage of specifying what content is to-be-remembered during the task rather than
having to interpret what the animal remembered. Stern et al., (2001) suggests that during
the DNMS task, repeated presentations of small numbers of stimuli can result in
significantly slower learning and reduced performance in nonhuman primates.
Additionally, the literature suggests that rats trained on DMNS tasks which use repeated
stimuli are not able to learn the task as easily as a DNMS with unique stimuli
(Dudchenko, 2004; Wood et al., 1999). Such evidence may indicate that there is a
fundamental difference in the memory systems used to encode familiar vs unique stimuli.
The repeated use of a small set of familiar stimuli requires the subject to maintain the
information about the stimuli leading to the possibility of interference effects (Schon et
al., 2008). Whereas unique stimuli do not produce the same interference effects and have
been shown to be more reliant on recognition memory and hippocampally dependent
(Mumby, 2001). It is likely that the PFC is responsible for maintaining active
representations of stimuli during the DNMS in order to avoid interference effects
(Dudchenko, 2004; Stern et al., 2001), another feature commonly associated with
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working memory functioning. Davies et al. (2013,2017) have shown that in rats, the
mPFC is needed to maintain performance on working memory span tasks. An idea that is
supported by lesion studies showing that damage to the PFC results in stronger
impairments on the DNMS with 8 but not 16 odors (Stern et al., 2001). Therefore, a
DNMS task which makes use of a small number of repeated stimuli may represent more
ethologically valid measure of the PFC involvement of working memory.
Models of the Pathophysiology of Depression in Humans
Despite the high prevalence rates and clear socioeconomic burden, there is little
agreement on the pathophysiological mechanisms behind major depressive disorder.
Studies indicate that cognitive impairments seen in MDD are the result of neurobiological
abnormalities, which have been observed using structural and functional neuroimaging
techniques (Barch et al., 2003; Matsuo et al., 2007; Pu et al., 2011). However, it should
be noted that these studies also suffer from inconsistent results showing differences in
activation patterns or in structure/functional form. Patients with MDD have physiological
and hemodynamic changes in areas like the hippocampus, amygdala, caudate nucleus,
putamen and prefrontal cortex (PFC) (Chiriţă et al., 2015; Matsuo et al., 2007; Pu et al.,
2011). Additionally, studies report reductions in glial cell counts, and deceased neuronal
size and/or synaptic proteins within these regions (Rajkowska et al., 1999). Using
positron emission tomography, it has been found that depressed patients display
significant reductions in PFC volume which appears to be correlated with the duration of
the disorder. The evidence suggests that this reduction in volume is not necessarily due to
neuronal loss, as the literature often suggests, but rather in reductions of synapses which
is evidenced by reduced ligand binding (Hare & Duman., 2020). Such changes in the
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structure/function of the PFC are also observed animal studies which show that chronic
stress models of depression can reduce the density of dendritic spines in areas like the
mPFC.
The PFC has been implicated in the functioning of personality, awareness, and
cognition including working memory, and MDD-related mood symptoms. Investigations
into the physiology behind depression using populations with treatment resistant
depression have shed light on the importance of the PFC in depressive symptomology.
Application of deep brain stimulation within areas like the subgenual cingulate
(Brodmann area 25) markedly improves mood with some capacity to improve cognitive
functioning (Mayberg et al., 2005; McNeely et al., 2008). Interestingly, the improvement
in mood and cognitive functioning observed by McNeely and colleagues (2008) was not
statistically correlated. Lending further support to the idea the cognitive dysfunction is a
separate domain of depression distinct from mood symptoms. Damage to the PFC
results in significant deficits in tasks designed to measure working memory (Bechara,
Damasio, Tranel, & Anderson, 1998; Müller & Knight, 2006). More specifically, the
dorsolateral prefrontal cortex in human and nonhuman primates has been shown to be
involved with working memory (Granon, Vidal, Thinus-Blanc, Changeux, & Poucet,
1994). In human patients with MDD, scores on working memory test such as the n-back
are significantly lower compared to healthy controls (Matsuo et al., 2007). Matsuo et al.,
(2007) showed that healthy individuals had bilateral activation of the DLPFC, left
inferior frontal gyrus, and anterior cingulate (ACC) during the n-back task compared to
patients with MDD which had greater activation (hyperactivation) in the left PFC and
cingulate cortex during working memory tasks. fMRI studies have supported the role of
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the PFC’s ability to maintain consistent responses to repeated presentations of stimuli.
The PFC is preferentially engaged when prior representations already exist in the brain
and must be selectively updated and monitored to avoid interference(Stern, Sherman,
Kirchhoff, & Hasselmo, 2001). Such evidence suggests that activity within the corticolimbic circuit may serve an important role in working memory function (Matsuo et al.,
2007). Conversely, Barch et al., (2003) observed that there are no differences in PFC
activation on the n-back task between MDD patients and healthy controls using fMRI.
Others have also suggested that there is hypoactivation rather than hyperactivation in the
PFC of MDD patients (Pu et al., 2011). Therefore, it should be clear that the association
between frontal activation and task performance is not always consistent and there must
be a more complex explanation underlying these differences.
The Pharmacological Characteristics of Metabotropic Glutamate Receptors 2 and 3
Within the prefrontal cortex glutamate is the primary excitatory neurotransmitter.
Glutamate receptors can be divided into two types based on their method of activation
and so are referred to as either ionotropic glutamate receptors (iGlu receptors) or
metabotropic glutamate receptors (mGlu receptors). iGlu receptors contain specialized
ion channels that have selective affinities for N-methyl-D-aspartate (NMDA), α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate.
The mGlu receptor class can be divided into three subgroups and eight distinct
subtypes. Metabotropic glutamate receptors are grouped together based on sequence
homology, intracellular second messengers, ligand selectivity and pharmacological
properties. Group Ⅱ (mGlu receptor 2 and mGlu receptor 3) mGlu receptors share
roughly 67% sequence homology and are coupled to Gi/o G-protein alpha subunits
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(Cartmell & Schoepp, 2002; Chaki, Ago, Palucha-Paniewiera, & Pilc, 2013; Gu et al.,
2008a; Ottersen & Landsend, 1997; G. Richards et al., 2005). mGlu 2/3 receptors binding
to Gi/o negatively regulates intracellular cAMP levels, leading to inhibition of voltagegated calcium channels. Interestingly, a majority of the studies that have investigated the
effects of group Ⅱ mGlu receptor effects on calcium channel inhibition have done so
using mGlu 2/3 receptor agonists while observing postsynaptic activity in areas like the
neocortex, hippocampus (CA1 and CA3), and the striatum. The evidence suggests that
this inhibition occurs most commonly in N-type calcium channels but also in L-type and
P/Q type channels. N-type calcium channel inhibition can occur relatively fast by Group
Ⅱ selective agonists in a way that appears to be the result of a direct membrane delimiting
action involving the G-protein rather than a diffusible intracellular second messenger.
Inhibition of these N-type calcium channels appears to be related to the slowing of
activation kinetics within isolated neocortical neurons as well as human embryo kidney
cells (HEK) that express both mGlu 2/3 receptors. Whereas the blocking of L-type
inhibition can be generated by external Ca2+ in neocortical pyramidal cells and appears to
occur in a relatively slow manner, which fits that characteristics of a diffusible
intracellular second messenger. Little work has been done of the effects of P/Q calcium
channel inhibition, but the data suggests that they can be blocked by (1R)-1aminocyclopentane-1,3-dicarboxylic acid (t-ACPD), (1R,2R)-3-[(S)amino(carboxy)methyl]cyclopropane-1,2-dicarboxylic acid (DCG-IV) and quisqualate in
the frontal and parietal cortices. Additionally, G-protein βγ subunits may directly
stimulate inhibitory G protein inwardly rectifying potassium channels (GIRKs). mGlu
receptors 2/3 functional coexpression on GIRK subunits has led to the finding that group
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Ⅱ mGlu receptor agonist can activate inhibitory GIRK-mediated currents (Anwyl, 1999;
Dutar et al., 1999, 2000; Knoflach & Kemp., 1998).
In either case, activation of mGlu 2/3 receptors induces modulatory inhibitory
effects on cellular activation which may make them good candidates for drug targets.
Compared to iGlu receptors, group Ⅱ mGlu receptors may have to potential to act as drug
targets for depression and anxiety treatments. The activation of iGlu receptors often lead
to excitotoxic effects, and inhibition can have serious health side effects (Wierońska &
Pilc, 2009). Evidence suggests group Ⅱ mGlu receptors can be expressed either pre-orpostsynaptically(Gu et al., 2008b; Neki et al., 1996). Presynaptic mGlu 2/3 receptors
could decrease neurotransmitter release via voltage-gated calcium channel inhibition.
Postsynaptically expressed mGlu 2/3 receptors can potentially stimulate GIRKS or alter
cAMP regulation to reduce cellular depolarizations (Anwyl, 1999; Iacovelli, Nicoletti, &
De Blasi, 2013; Johnson & Schoepp, 2008; Suh, Kai, & Roche, 2018). A result of sharing
such a close sequence makes understanding how the mGlu 2/3 receptors are distributed,
and their functional properties a challenge to the field.
Among the mGlu receptor ligands exists agonists such as (1S,2S,5R,6S)-2aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), (1S,2R,5R,6R)-2-amino4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), (2R,4R)-4aminopyrrolidine-2,4-dicarboxylic acid (LY314593), DCG-IV, (1S,2S)-2-[(1S)-1-amino2-hydroxy-2-oxoethyl]cyclopropane-1-carboxylic acid (L-CCG-I), and (4S,6S)-4-amino2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY389795) which the literature
suggests are selective for group Ⅱ mGlu 2/3 receptors. There are also mGlu 2/3 receptor
selective antagonists like (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-
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yl)propanoic acid (LY341495), (1S,2S)-2-[(2S)-2-amino-1-hydroxy-1-oxopropan-2yl]cyclopropane-1-carboxylic acid (MCCG), (1R,2R,3R,5R,6R)-2-amino-3-[(3,4dichlorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
(MGS0039) (Johnson & Schoepp, 2008). Most of the known mGlu 2/3 receptor ligands
cross-react, and only a few can discriminate between the two receptor types which has
important implications when considering their distributions and functional roles. For
more details about the affinities of LY341495 and LY354740 for mGlu receptors see
Table 1. Antagonism of mGlu 2/3 receptors is thought to possess antidepressant like
effects in tasks like the force swim test, tail suspension test, and the learned helplessness
test in rodents (Bespalov et al., 2008; Wierońska & Pilc, 2009).
Regional Distribution of Metabotropic Glutamate Receptors 2 and 3
There have been several attempts to map the distribution of Group Ⅱ mGlu
receptors, using techniques such as autoradiography, immunohistochemistry, and in situ
hybridization, but not all report consistent results. Investigations into the distribution of
mGlu 2/3 receptors based on mRNA expression and immunoreactivity suggest they are
localized on neurons and glia in areas associated with higher cognitive functions
(Prefrontal Cortex, Hippocampus, Amygdala, Basal Ganglia) and areas involved in
sensory perceptions (Olfactory bulb, Somatosensory Cortex, Thalamus: Cartmell &
Schoepp, 2002; Feyissa et al., 2010; Ohishi, Shigemoto, Nakanishi, & Mizuno, 1993a,
1993b; Tanabe et al., 1993, Marek, 2010). Immunostaining using an antibody which
identified both mGlu 2 receptors and mGlu 3 receptors indicated that mGlu 2/3 receptors
are moderately expressed on neurons and in the neuropil of the cerebral cortex.
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Throughout the rodent neocortex, immunostaining of mGlu 2/3 receptors was
light to moderate with higher levels observed in layers Ⅰ, Ⅲ and Ⅳ compared to layers Ⅱ,
Ⅴ, Ⅵ. Staining on neurons was largely observed on small/medium neurons in many of
the layers, with scattered staining seen on pyramidal neurons in layers Ⅲ and Ⅴ. The
pattern of immunoreactivity in the neocortex appears to correspond well with distribution
mGlu 2/3 receptor mRNA transcripts (Petralia et al., 1996; Richards & Ruff, 1989). In
the hippocampus, mGlu 2/3 receptors immunostaining was light to moderately observed
in areas CA1-CA3. In areas CA1-CA3 mGlu 2/3 receptor immunoreactivity was
commonly found on the neuropil and irregular processes located between pyramidal
neurons. There was little evidence for labeling on neuronal cell bodies, but some labeling
was observed on pyramidal neurons in areas CA1. Additionally, in areas CA1-CA3 light
to moderate staining was seen on glial cell bodies and processes assumed to be astroglia.
In areas of the hippocampal formation like the dentate gyrus, moderate levels of
immunolabeling was seen on granular and molecular layers. Immunolabeling extended
into the layers of the entorhinal cortex and was largely seen in the neuropil with only few
neurons expressing immunoreactivity. Overall, the pattern of immunoreactivity observed
in the hippocampal formation corresponds well with the distribution of mRNA seen by
Richards et al., (2005). Immunoreactivity in the basal ganglia was seen largely in the
neuropil in a light to moderate manner with densest staining in striatum. Within the
striatum, immunoreactivity was dense and seen throughout whole of the structure. The
observed immunoreactive cells were largely neuropil with only scattered expression on
neurons and dendrites. Interestingly, mGlu 2 mRNA appeared to be absent in the striatum
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but mGlu 3 mRNA could be clearly seen throughout the structure (Petralia et al., 1996;
Richards & Ruff, 1989).
In humans, mGlu 3 mRNA was localized on neurons in the cerebral cortex, and
highly expressed within the white matter. Expression within the dentate gyrus was similar
to that seen in rodent granular layers(Harrison et al., 2008).While the studies of human
mRNA expression of group Ⅱ mGlu receptors can differentiate between mGlu 2 and
mGlu 3 receptors, majority of the studies that have used mGlu 2/3 immunoreactive
antibodies cannot. Harrison et al. (2008) indicates that immunolabeling is present within
white matter, and on structures like the striatum, hippocampus, and PFC with strongest
expression in the neocortex. In the frontal cortices labeling was not expressed on neurons,
dendrites, or glial cell bodies, and exhibited a pre-perisynaptic localization. Within the
hippocampus, mGlu 2/3 receptor immunoreactivity is present throughout the structure
(CA1-CA4 and dentate gyrus), and localized on granular and pyramidal neurons, glia,
and neuropil.
Cellular and Subcellular Distribution of Metabotropic Glutamate Receptor 2
On a subcellular level, mGlu 2 receptors are expressed predominantly on neurons
with some evidence suggesting they are also found on glia (Ohishi et al., 1993a; Ghose et
al., 2008). The localization of the mGlu 2 receptor appears to favor pre- and peri-synaptic
zones that are situated away from the synaptic site of activity, with some evidence for
post-synaptic expression (Anwyl, 1999; Cartmell & Schoepp, 2002; Neki et al., 1996;
Petralia et al., 1996; Richards et al., 2005). In the neocortex, mGlu 2 mRNA was weak to
moderately observed in all layers Ⅰ-Ⅵ. mRNA expression was most dense in layer Ⅳ and
least dense in layers Ⅰ and Ⅵ. mRNA transcripts were present on pyramidal and non-
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pyramidal neurons in all layers except layer Ⅰ (Gu et al., 2008b; Ohishi et al., 1993a).
Observations of mGlu 2 receptor immunoreactive cells show a similar pattern of
distribution compared to mGlu 2 mRNA transcripts. Some differences within the layers
indicate a stronger localization in layers Ⅱ-Ⅴ (Gu et al., 2008b). In the hippocampus
mGlu 2 receptor mRNA labeling was irregularly distributed in areas CA1-CA3, and
widely expressed in the granular layer of the dentate gyrus (Ohishi et al., 1993a). The
levels of immunoreactivity in hippocampal areas CA1-CA3 matched the mRNA
expression in these areas, as well as within the granular layer of dentate gyrus (Ohishi et
al., 1993a). Gu et al., (2007) also reported intense immunolabeling from the dentate
mossy fibers extending into the hippocampal area CA3. While much of the
immunoreactivity in the hippocampal formation match the mRNA expression, Gu et al.,
(2007) observed different levels of immunoreactivity in the dentate gyrus. The level of
intensity seen by Gu and colleagues (2007) indicated that mGlu 2 labeling throughout the
dentate was only low to moderate, with the observed intensity on individual granular cells
appearing to be only moderately intense. Such differences may be explained by the
ability for the antibody to identify mGlu 2 proteins. In the striatum there was only a light
level of mGlu 2 mRNA expression observed throughout the entire structure with mGlu 2
receptors mRNA being weakly expressed on neurons (Gu et al., 2008b; Ohishi et al.,
1993a). Immunoreactivity in the striatum confirms the weak and sporadic distribution of
mGlu 2 mRNA (Gu et al., 2008a). Additional evidence suggests that mGlu 2 receptors
can function as heterodimers with other receptors such as mGlu3, mGlu 4, and
serotonergic 5HT2A receptors (Doumazane et al., 2011; J. Liu et al., 2017; Schoepp,
2001). Based on the localization and electrophysiological evidence, mGlu 2 receptors
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may play a role as presynaptic autoreceptors that inhibit the release of glutamate and
possibly other neurotransmitters under high frequency stimulation (Chaki et al., 2013;
Iacovelli et al., 2013; Lovinger & McCool, 1995; Schoepp, 2001).
Cellular and Subcellular Distribution of Metabotropic Glutamate Receptor 3
Research into distribution pattern of the mGlu 3 receptor mRNA and
immunoreactivity indicates they are expressed predominantly on neurons and glia.
Evidence suggests that the mGlu 3 receptor is localized on the periphery and away from
the postsynaptic site of action (Anwyl, 1999; Cartmell & Schoepp, 2002; Ohishi et al.,
1993b; Petralia et al., 1996; G. Richards et al., 2005). However, because of the poor
ability for group Ⅱ mGlu receptor ligands to discriminate between mGlu 2 receptors and
mGlu 3 receptors, distribution and localization patterns suggested by the literature may
not be accurate. Using mGlu 2 receptor knockout mice and a mGlu 3 receptor specific
antibody indicates that presynaptic mGlu 3 receptors are localized away from the
synaptic zone of activity, whereas postsynaptic mGlu 3 receptors are localized closer to
synapse (Johnson & Schoepp, 2008; Tamaru et al., 2001). The mGlu 3 receptor appears
to have less neuronal expression and higher glial expression compared to the mGlu 2
receptor but is distributed in many of the same regions (Ohishi et al., 1993b). In the
cerebral neocortex of mice, mGlu 3 receptors immunoreactivity was found diffusely in all
layers, with strongest expression in layers Ⅰ-Ⅲ, weaker in Ⅳ-Ⅵ, and diffusely
throughout the neuropil. In the cingulate cortex, mGlu 3 receptor immunostaining was
diffusely distributed in a pattern similar to the neocortex (Ⅰ-Ⅲ > Ⅳ-Ⅵ). Within the
hippocampus, mGlu 3 receptor immunoreactivity in area CA1 was weakly expressed in
the neuropil of the stratum lacunmosum moleculare, and moderate in the strata radiatum
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and oriens. In area CA3 stratum lacunmosum moleculare, intense staining was seen in the
neuropil, with moderate expression in the strata radiatum and oriens. Additionally, mGlu
3 receptor immunolabeling was intense in the neuropil of dentate gyrus molecular layer
and the striatum (McOmish et al., 2016; Tamaru et al., 2001).
Interestingly these immunostaining results in mice agree with the mRNA
localization of the mGlu 3 receptor in rats, but not with the intensity of the distribution
which may indicate a cross species difference in mGlu 3 receptor expression. In the
cerebral cortex mGlu 3 receptor mRNA was distributed on pyramidal and non-pyramidal
neurons, as well as glia cells such as astrocytes and oligodendrocytes. mGlu 3 receptor
mRNA has a moderate level of expression in neocortical layers Ⅳ-Ⅵ and is only weakly
labeled in layers Ⅰ-Ⅲ (Ohishi et al., 1993). mRNA staining was observed on both
pyramidal and nonpyramidal neurons in a weak to moderate level in these layers.
However, the expression of mGlu 3 mRNA does not appear to be consistent, Gu et al.,
(2007) observed a difference in the expression levels seen within the neocortex of rats
compared to Ohishi and colleagues (1993). Gu et al., (2007) saw mGlu 3 receptor mRNA
levels within the neocortex as being light to moderate, with lowest layer Ⅰ having the least
and layer Ⅳ having the highest expression. In layers Ⅱ, Ⅲ, Ⅴ, and Ⅵ mGlu 3 receptor
mRNA expression was considered light to moderate. Within the hippocampal formation,
weak to no mRNA staining observed in the stratum lacunmosum moleculare (CA1 only),
the stratum radiatum, pyramidal cell and granule cell layers of CA1 and CA3. In the
hippocampal granular layer, mGlu 3 receptor mRNA labeled cells were irregularly
distributed on neurons and glia. mRNA labeling was seen throughout dentate gyrus was
intense, but only lightly expressed on individual granular cells. In the striatum and
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nucleus accumbens many neurons were weak to moderately labeled (Gu et al., 2008b;
Harrison et al., 2008; Johnson & Schoepp, 2008; Ohishi et al., 1993). Like the mGlu 2
receptors, the mGlu 3 receptors may form heterodimers and regulate the release of
glutamate and other neurotransmitters (Chaki et al., 2013; Johnson & Schoepp, 2008).
Role of Metabotropic Glutamate Receptors 2/3 and Glia in the Tripartite Synapse
The classical model of neurotransmission generally involves what is called a
bipartite synapse consisting of a pre-synaptic terminal and post-synaptic density. Such
bidirectional signaling has been observed in both neuron-neuron but also neuron-glia
transmission. A common type of neuron-glia transmission occurs with metabotropic
glutamate receptors and astrocytes (Wierońska & Pilc, 2009). Such interactions between
glia and neurons has led to the proposal of a three-way interacting synapse called the
tripartite synapse (Figure 1). The tripartite synapse is composed of three interactive
compartments: a presynaptic and postsynaptic terminal, and an astrocyte. Astrocytes are
known to receive inputs, process information and send signals to other cells, all without
being able to fire action potentials or conduct electrical excitability. Functionally,
astrocytes play a role in neuroprotection and plasticity, suggesting they may be involved
with a variety of neurocognitive disease pathologies. A common hallmark of depression
pathology is the reduction in glia-to-neuron ratio (Sanacora et al., 2012). Astrocytic loss
could explain the dysregulation in glutamatergic signaling observed in depressed patients.
Interestingly, astrocytes possess g-protein coupled receptor sites for many
neurotransmitters, such as mGlu 3 receptors. In areas like the cerebral cortex, mGlu 3
receptors have higher expression rates on glial processes compared to synaptic terminals.
Such glial processes are also commonly found around other neurotransmitter terminals
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such as GABA (Wierońska & Pilc, 2009). For a model of the distribution of mGlu 2/3
receptors at the tripartite synapse see Figure 1.
Once activated, mGlu receptors localized on astrocytes can regulate excitatory
synaptic transmission by controlling the levels of extracellular glutamate through the
release of gliotransmitters. Such activation is generally associated with increased uptake
or removal of glutamate from the synaptic cleft which would decrease excitatory
signaling. Therefore, antagonism of astrocytic mGlu 3 receptors could increase levels of
synaptic glutamate and excitatory signaling. (Wierońska & Pilc, 2009).
Hypothesized Role of Metabotropic Glutamate Receptors 2 and 3 in Rat
The importance of glutamate neurotransmission can be seen in its relationship to
cognitive functions like learning and memory. Glutamatergic synapses play a role in both
long-term potentiation (LTP) and long-term depression (LTD), both of which are
important factors for the integration of new information (Sanacora et al., 2012). The
existing literature indicates that decreases in excitatory activity within the frontal cortex
either impairs or improves cognitive function. The group Ⅱ mGlu 2/3 receptor subtypes
are widely expressed in brain regions important for short-term and working memory
(frontal cortex/ mPFC) (Johnson & Schoepp, 2008; Ohishi et al., 1993a,1993b).
Localization studies suggest mGlu 2/3 receptors are expressed pre-post-synaptically and
in the periphery away from the synaptic zone of activity. Activation of presynaptic mGlu
2/3 receptors regulates the release of and prevents excessive buildup of glutamate. In
addition, activation of postsynaptic mGlu 2/3 receptors can negatively modulate neuronal
excitability through intracellular mechanisms. mGlu 2/3 receptors agonists reduce
activity of the host cell through inhibition of calcium channels or activation of GIRKS
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(Johnson & Schoepp, 2001). Antagonization of the mGlu 2/3 receptors should lead to an
increase in glutamate neurotransmission through a combination of neuronal and glial
mechanisms. This ability to modulate excitatory activity is worth investigation given the
abundance of glutamatergic pyramidal cells within the frontal cortex compared to
inhibitory GABAergic cells, as well as the ability for mGlu 2/3 receptors to form
heterodimers and to regulate the release of other neurotransmitter receptors (GABA,
Dopamine, 5-HT2A) (Chaki et al., 2013; Johnson & Schoepp, 2008).
It has been previously hypothesized that increasing glutamate neurotransmission
should improve cognitive function (Gregory et al., 2003; Pehrson et al., 2016). In
congruence with this, it has been proposed that using the mGlu 2/3 receptor antagonist
LY341495 to increase glutamate levels in would facilitate cognitive performance on
short-term working memory tasks (Gregory et al., 2003; Higgins et al., 2004). Given that
the DNMS is considered to be a working memory task, we hypothesize here that
increasing the temporal delays between information and retention trials will decrease
overall task accuracy. Additionally, we hypothesize that increasing levels of neuronal
glutamate in the rat brain via the group Ⅱ mGlu receptor antagonist LY341495 would
facilitate performance during the odor based delayed-non-match-to-sample task.
Methods
Subjects
Twenty-two Male Long Evans male rats (age 6-8 weeks, Envigo) were tested
using a within-subjects design. After arriving to the facility, the rats were paired housed,
and placed in a room with a 12hr light/dark cycle (8:00AM to 8:00PM). For one week,
the rats had ad libitum access to food and water. Otherwise, the rats had ad libitium
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access to water and were placed on a diet to maintain them at 90% of their free feeding
weight. Experiments were approved by and conducted in accordance with the Montclair
State University Institutional Animal Care and Use Committee and were consistent with
the Guide for the Care and Use of Laboratory Animals (2010).
Apparatus
An open field platform designed according to the specifications of Davies et al.
(2004) (91cm L x 91cm W x 91cm H) with a (5 cm) surrounding wall was used throughout
the training and testing procedures (see Figure 2). The platform was fastened to a pole
which sat 91 cm off the floor. The platform was placed inside of an arrangement of four
black welders’ currents to block out any external visual cues. To secure the Nalgene cups
(2.5cm D x 2.9cm H) to the open field, they were attached to Velcro strips that were
evenly spaced 14 cm apart, and 8cm in from the wall.
Drugs
(2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propionic acid
(LY341495) disodium salt was purchased from Tocris Bioscience (Minneapolis, MN).
LY341495 was dissolved in sterile saline and pH was adjusted to 7.2-7.8. Vehicle or
LY341495 was administered intraperitoneally (I.P.) 30 minutes prior to the start of
behavioral testing. LY341495 was administered at final doses of 0.3, 1, or 3 mg/kg.
Doses represent the mass of the active base, not the salt. All injections were administered
at a volume of 1 mL/kg of body weight.
Odors
The odor cues were a mixture of sand (Sakrete; Atlanta, Georgia) and spices (see
Table 2) that were placed inside of the Nalgene cups. The sand mixtures consisted of
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(99.5 grams) sand and (0.5 grams) a single dry spice with a powered consistency (any dry
leaf spices were ground to a powder using a mortar and pestle). Initially, the experiment
started with 12 scents. However, because of suspected difficulty differentiating between
two scents (e.g. cumin seed, and basil), those two were replaced with two different scents
(e.g. lemon peel, and thyme). In total 14 scents were used throughout the duration of the
experiment. All the spices were store-bought, and brand remained consistent when
replenished. The odors and odor sequences used for a particular day were selected using
Random.org’s random list generator. For a single testing day all rats experienced the
same odors but the order at which the odors were presented were randomized for each
individual.
Habituation
Rats were handled individually for five minutes once a day for one week prior to
training. After the week of handling, each rat individually experienced a single fiveminute habituation session to acclimate them to environment of the open field.
Shaping Training
Following the habituation training, the rats were trained how to dig for a food
reward (Fruit Loops, Kellogg’s, Battle Creek, Michigan) that was buried in unscented
sand. The shaping training consisted of three consecutive phases. In phase one, the rats
were allowed to explore the open field with a single cup of unscented sand with the food
reward placed on top of the sand and in the middle of the cup. Once the rat consumed the
reward they were removed from the open field. During all of the phases and between
each rat, the field was cleaned with a Virkon cleaning solution (Lanxess, Cologne,
Germany). Phase two consisted of the same unscented sand cup but with the food reward
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partially buried in the sand. The third phase again used the same unscented sand cup, but
the food reward was fully buried (3 mm deep) in the sand. Throughout phases one and
two, the rats had an unlimited amount of time to explore and retrieve the reward.
Exploration time for phase three was reduced to 5minutes. After experiencing all three
phases within a single day, training consisted of a single phase three testing session
where the rat had five minutes to explore and retrieve the food.
Group Ⅱ had a time limit of 5 minutes established for all three phases of the
training and experienced all three phases daily. In total, shaping training spanned a total
of 5 to 25 days, depending on the performance of individual animals.
When a rat was consistently failing to meet the time criteria and was considered to
as having difficulty understanding the task. Standard shaping training as standard above
was replaced with an incremental digging training which consisted of the following.
These incremental sessions included six trials in which the food reward got buried deeper
until it was buried 3mm deep by the final trial. The passing criteria for the shaping
training required the rats to be able to retrieve the food reward within thirty seconds for
three consecutive testing days. Of the twenty-two rats that experienced the shaping
training, twenty-one successfully completed the training within an average of 13 sessions,
see Figure 7A.
Non-matching-to-Sample Task
Once the rats met passing criteria for shaping training, they began training on the
non-matching-to-sample task (NMS). This experiment utilized a modified version of the
NMS as described in (Davies et al., 2013). The modification that was incorporated into
this study required the location of the stimulus cups to be fully randomized in both the
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information and retention trial. All locations were randomly generated using a random
sequence generator and then pseudo-randomly assigned to avoid instances with repeated
locations between trials. During the information trial, the rats had to retrieve a fully
buried food reward from a single cup of scented sand mixture. Once the rats consumed
the food reward they were removed and placed in their home cage. For the retention trial,
the rats were presented with both the original scented sand mixture without the reward,
and a cup containing different novel scented sand with a fully buried reward. The rat’s
choice was scored as correct if they removed the reward from the novel scented cup
without touching the original cup from the information trial. For both the information and
retention trials, the rats had a maximum of 30 seconds to retrieve the reward, which was
the minimum speed at which the trials could be setup. The training criterion for NMS
training required the rats to score a minimum of 5:6 correct trials for three consecutive
testing days. If the rats experienced difficulty in learning the task, they were given
incremental digging training across all six sessions until they could reliably retrieve the
reward. The NMS training the Group Ⅰ and Group Ⅱ rats experienced were
methodologically identical. Of the twenty-one rats that began the NMS training, 14
completed the training (mean 16 sessions).
Delayed Non-matching to Sample Task
Once the rats were able to reliable pass the NMS and successfully completed the
supplementary experiments, they moved onto the delayed non-match-to sample task
(DNMS). The setup and procedure for the DNMS was the same as the NMS but used an
intertrial time interval (ITI) between the information and retention trials that was
established from the results of the supplementary experiment 1. The ITI used in the
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DNMS was 100 seconds which was judged as being an ITI that could have room for
improved task accuracy.
Experimental Design
Supplementary Experiment 1: Assessing the Effects of Time on Memory Performance
The NMS task as a measure of working memory should be expected to have
decreased performance as the time interval between information and retention trials gets
longer. To investigate this aspect of the NMS task, all rats that met NMS passing criteria
were assigned four different intertrial time intervals (30, 100, 300, and 1000 seconds)
using a Randomized Latin square design.
Supplementary Experiment 2: Assessing the Use of Alternate Task Completion
Strategies
All rats (n=14) that met NMS criteria were given two probes that investigated
whether the rats were marking the cups during the trials, or if they were using the scent of
the food reward as a guide. The reward probe proceeded the same as the regular NMS
task, but the food reward was removed from the novel cup during the retention trial. If the
novel cup was selected, the food reward was placed on top of the sand. To rule out the
possibility that the rats were marking the cups. The odor probe replaced the original cup
present during the information trial with a new cup containing the same scent as the
original. If the rats failed to meet NMS criteria during either probe trial, they were
removed from the NMS training before beginning drug trials.
Primary Experiment: The Effects of LY341495 DNMS Task Performance
The rats that proceeded onto the DNMS LY341495 trials (n=11) had previously
completed the NMS training, the NMS ITI, and the NMS supplementary probes. The
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LY341495 DNMS task was methodologically identical to the DNMS task stated above. It
consisted of six sessions (12 trials) with a 100 second ITI between the information and
retention trials. LY341495 dosing during the DNMS used a within-subjects design, and
the order of dosing (vehicle, 0.3, 1, 3 mg/kg) was determined using a randomized Latin
square design. LY341495 doses were all administered via intraperitoneal (I.P) injections
30 minutes prior to the start of the initial information trial. For a single testing day, each
rat received a single dose, and were exposed to one testing session consisting of six trials.
Between each dosing day the rats were retested on the regular DNMS task to ensure they
could still perform the task. During the LY341495 trials 3 rats failed to reach the DNMS
criteria and were removed from the LY341495 trials. A total of 8 rats completed the
LY341495 trials.
Data Analysis
The primary dependent measure was defined a priori as an accuracy
measurement, expressed as a percentage of the total number of trials within a given test
session in which a correct choice was made during a given test session for an individual
animal. Secondary dependent measures included latency to choose a digging pot, and the
distance traveled during the information and retention trials (collected by SMART video
tracking software, Harvard Apparatus, Holliston, MA).
Inferential statistical analysis for all dependent measures was conducted using the
same analysis plan, which was defined a priori. First, data was checked for normality
using the Lilliefors test. In cases where data was distributed normally, data was analyzed
using a one-way repeated measures ANOVA, with Tukey-Kramer post hoc tests where
appropriate. In cases where data was not distributed normally, data was analyzed using
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Friedman’s test, followed where appropriate by the Wilcoxon-Ranked Sign post hoc
tests. All data are expressed as mean ± standard error of the mean (SEM), and alpha was
set at 0.05.
Results
Probe Trial Data
Raw data for probe trials are presented in Table 3. There was a total of 14 rats that
were tested on the probe trials, all data are presented in Figure 5. The passing criteria was
set the same as the DNMS ≥ 83.3% accuracy. During the reward probe all 14 rats passed
with 100% accuracy, indicating that the rats were not guided by the scent of the reward.
Inspection of the accuracy data during the marking probe revealed that three rats were
guided by some form of marking odor, achieving less than < 83.3% accuracy. The three
rats which failed the marking probe were removed from the study leaving 11 rats to
proceed onto the LY341495 DNMS trials.
A description of sample sizes after each stage of training, probe trials, or testing
can be found in Figure 3.
Time Course Data
Raw data for ITI trials is presented in Table 4. To validate the DNMS as a
working memory task the effects of the inter-trial-interval (ITI) on the accuracy data are
presented in Figure 6. Investigation of the ITI accuracy data using the Lilliefors’s test of
normality indicates that the data was not normally distributed (Dn = 0.15625, p < 0.05),
therefore the non-parametric Friedman’s test was used for inferential analysis. The results
of the Friedman’s test on the accuracy data during the ITIs suggests that the data is
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significantly different compared to the accuracy at the ITI of (χ2(3) = 16.4, p < 0.05). We
used Kendall’s W to measure effect size for the Friedman’s test, and found a value of
0.681, which is interpreted as a moderate effect size and indicates the data points are in
moderate agreement with each other. Post hoc analysis with the Wilcoxon signed-rank
test revealed there was a significant difference between the 30 seconds and 100 seconds
(Z = -3.09, p < 0.05), 30 seconds and 300 seconds (Z = -3.42, p < 0.05 ), and 30 seconds
and 1000 seconds (Z= -3.39, p < 0.05).
LY341495 Effects on the DNMS Task
During the course of the LY341495 DNMS task three rats were removed because
of failure to achieve passing criteria on follow-up testing. All data from the LY341495
DNMS task (n=8) are as follows.
The Effects of LY341495 on DNMS Task Accuracy
Raw data for LY341495 DNMS trials is presented in Table 5. The effects of
LY341495 on accuracy data are presented in Figure 7. Investigation of the accuracy data
using the Lilliefors’s test of normality indicates that the data was not normally distributed
(Dn = 0.18975, p < 0.05), therefore the non-parametric Friedman’s test was used for
inferential analysis. The results of the Friedman’s test suggest that LY341495 dose had a
significant effect on accuracy (χ2(3) = 9.6, p < 0.05). We used Kendall’s W to measure
effect size for the Friedman’s test, and found a value of 0.398, which is interpreted as a
moderate effect size and indicates the data points are in moderate agreement with each
other. Post hoc analysis with the Wilcoxon signed-rank test revealed there was no
differences between the vehicle and 0.3 mg/kg doses (Z = -1.51, n.s.) or the vehicle and 1

GROUP II MGLU RECEPTORS AND COGNITION

P a g e | 37

mg/kg doses (Z = -0.412, n.s.). However, there was a statistically significant decrease
between the vehicle and 3 mg/kg doses (Z = -2.48, p < 0.05).
The Effects of LY341495 on DNMS Distance Traveled
Raw data for LY341495 DNMS trials is presented in Table 5. The effects of
LY341495 on distance traveled data are presented in Figure 8. The assumption of
normality was checked using the Lilliefors’s test which showed that the data was
normally distributed (Dn = 0.1205, n.s.), therefore we could proceed with the inferential
analysis using a one-way repeated measures ANOVA. The results of the ANOVA
indicated there was a statistically significant difference between the groups for the
distance traveled data as determined by the one-way repeated measures ANOVA (F(3,27)
= 4.588, p = .0127). This analysis was associated with an η2 of 0.284, which indicates the
data had a moderately large effect size. We used a post hoc analysis using the Tukey’s
HSD method showed there was no statistically significant difference between the
distances traveled at any of the doses (0.3, 1 and 3 mg/kg) compared to vehicle.
The Effects of LY341495 on DNMS Latency to Retrieve the Reward
Raw data for LY341495 DNMS trials is presented in Table 5. The effects of
LY341495 on latency to retrieve the reward data are presented in Figure 8. We used the
Lilliefors’s test to check the assumption of normality, which indicated that the data was
not normally distributed (Dn = 0.25915, p < 0.05), therefore the non-parametric
Friedman’s test for inferential statistics is appropriate. Analysis of the latency data using
the Friedman’s test indicated that LY341495 had a significant effect on response latency
(χ2(3) = 11.8, p = 0.00792); W= 0.494). We used Kendall’s W to measure effect size for
the Friedman’s test, and found a value of 0.494, which is interpreted as a moderate effect

GROUP II MGLU RECEPTORS AND COGNITION

P a g e | 38

size and indicates the data points are in moderate agreement with each other. Post hoc
analysis using the Wilcoxon signed-rank test revealed that there were no detectable
differences between the vehicle and the 0.3 mg/kg dose (Z= -1.73, n.s). However, there
was a statistically significant increase in latency between the vehicle dose and the 1
mg/kg (Z = -2.58, p < 0.5), as well as the vehicle dose and the 3 mg/kg (Z= -2.26, p <
0.5).
The Effects of LY341495 on DNMS Locomotor Speed
Raw data for LY341495 DNMS trials is presented in Table 5. The effects of
LY341495 on locomotor speed data are presented in Figure 8. Using the Lilliefors’s test
of normality revealed that the latency data was normally distributed (Dn = 0.13914, p >
0.05), therefore we can proceed with a one-way repeated measures ANOVA. Results of
the one-way repeated measures ANOVA on the locomotor speed traveled at indicates that
there were no statistically significant differences between the groups (F(3,27) = 1.026,
n.s, η2 = 0.232). Using the generalized eta-squared as a measure of effect size found a
value of (η2 = 0.232), which indicates the data had a large effect size.
Discussion
We hypothesized that by increasing the temporal delays (ITI) between the DNMS
information and retention trials there would be an overall decrease in task accuracy.
Analysis of the ITI data indicates that this hypothesis was correct, and that task accuracy
dropped with increasing ITIs. Additionally, it was hypothesized that increasing the levels
of neuronal glutamate in the rat brain via the group 2 mGlu receptor antagonist
LY341495 would facilitate working memory performance during the DNMS task. Our
data suggests that administration of LY341495 during the DNMS impairs delayed non-
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match to sample performance in a dose-dependent manner, becoming statistically
significant at 3 mg/kg. The analysis of the distance the rats traveled during the task
indicated a significant main effect of treatment but did not differ between the dosing
groups. Furthermore, LY34195 treatment increased latency for the rats to remove the
food reward at 1 and 3 mg/kg doses. Finally, LY341495 did not alter locomotor speed
exhibited by the rats during the DNMS. There was no analysis done on measures such as
thigmotaxia. These data indicate that LY341495 administration impaired memory
function with limited effects on motor function.
The takeaway from the ITI data gives support to the idea that the DNMS task is a
working memory task. Increasing the ITI markedly reduced performance in the task.
Given that LY341495 is selective for group II mGlu receptors but unable to differentiate
between receptors in that class, and that each has a similar but unique distribution within
the CNS complicates our findings. Interpretations of the cognitive effects of LY341495
on DMNS accuracy indicate that increases in glutamate functioning may have a level at
which it can improve cognitive performance during the DNMS task. Support for this
comes from the accuracy data which indicates that while a 1 mg/kg dose was not
significantly different than vehicle, accuracy scores at this dose were higher compared to
0.3 and 3 mg/kg. Alternatively, it may suggest that the model of improving cognitive
functioning through increasing glutamate is too simplistic. The underlying mechanisms
controlling glutamate and its role in the CNS may be more complex than the current
literature suggests, a topic discussed further below.
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The Effects of mGlu 2/3 Agonism and Antagonism on Cognitive Function
When drawing comparisons about the effects of LY341495 on non-spatial
working memory functioning it is important to note that there are relatively few studies
that have explored this niche. With that, our results are somewhat consistent with the
literature of LY341495’s effect on cognitive functioning. Gregory and colleagues (2003)
showed that microinjections of the antagonist LY341495 directly into the PFC of rats
produces a trend towards increased performance during the forced choice delayedalternation task on a T-maze, a task often considered to model working memory
performance. Using the novel object recognition (NOR) test in rats, Pitsikas et al., (2012)
showed that LY341495 administered intraperitoneally at the same doses also impaired
the ability to perform the task. Interestingly, and most likely due to the differences in
neuronal systems activated during the NOR and DNMS, the observed decreases in the
NOR task performance were in the opposite direction as the DNMS (higher doses = less
impairment). Additionally, in mice LY341495 at both 1 and 3 mg/kg has been shown to
attenuate impairments in cognitive function during the delayed non-match to position
task produced by LY354740 (Higgins et al., 2004). Conversely, Gregory et al., (2003)
was showed that microinjections of LY341495 produced a trend towards increased
working memory performance on the forced choice delayed-alternation task using a Tmaze.
The results of LY341495 on measures of locomotion in the present study differ
somewhat from the literature. In the NOR task used by Pitsikas et al., (2012), LY34495
did not produce any off-target effects such as changes in locomotion, whereas it did in
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our DNMS task. However, in mice, administration of LY34195 significantly increased
the locomotor activity in a dose-dependent manner (Bespalov et al., 2007).
Interestingly, the literature suggests that antagonism and agonism of mGlu 2/3
receptors can produce similar effects on cognition. A common and selective drug used to
activate group 2 mGlu receptors is LY354740. Several studies using LY354740 indicate
that agonism of mGlu 2/3 receptors can impair working memory functions on a variety of
tasks and across species (Aultman & Moghaddam, 2001; Spinelli et al., 2005). However,
LY354740 can also attenuate working memory impairments produced by disruptions in
glutamatergic transmission (Aultman & Moghaddam, 2001; Krystal et al., 2005).
Application of LY354740 and LY341495 produces a competitive effect of mGlu 2/3
receptors. In some cases, LY341495 can attenuate the impairments produced by
LY354740 (Higgins et al., 2004).
The Role of mGluRs in Long-term Depression and Long-term Potentiation of
Synaptic Transmission
The reported inhibitory actions of mGlu 2/3 receptors in the CNS suggests that they
may play a significant role in the long-term depression of synaptic transmission, a form a
plasticity highly involved with learning and memory (Collingridge et al., 2010; Vose &
Stanton, 2016). The induction of LTD by mGlu 2/3 receptors is a phenomenon observed
it a variety of species such as humans, non-human primates, and rodents. Additionally,
LTD has been implicated in pathology of cognitive dysfunctions commonly seen in
depression. Within the mPFC mGlu 2/3 activation of receptors located in proximity to
layer V pyramidal cells (more specifically mGlu 3 receptors) have been observed to
suppress electrically-evoked excitatory postsynaptic potentials (EPSP) (Barbara et al.,
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2003; Xie & Steketee, 2009). Postsynaptic mGlu 2/3 induced LTD in areas like the PFC
through a variety of systems. In the PFC, LTD can be regulated through activation of
PKC and PKA pathways which can be regulated by postsynaptic group Ⅱ mGlu receptors
(Otani et al., 2002). Whereas, in the hippocampal areas CA1 and CA3 there is
contradiction about the role of mGlu 2/3 receptor induced LTD. By using mGlu 2
receptor knockout mice Yokoi and colleagues (1996) were able to show that mGlu 2
receptors are needed to induce LTD at the CA3 mossy fibers. However, pharmacological
evidence suggests that tonic activation of mGlu 2/3 receptors is not sufficient to induce
LTD within hippocampal areas CA1 and CA3 (Kemp & Bashir, 1999; Wostrack &
Dietrich, 2009). Group Ⅱ mGlu receptor mediated LTD has also been observed in areas
like amygdala, striatum, nucleus accumbens, and in the cerebellum (Kahn et al., 2001). In
the striatum, Kahn and colleagues (2001) were able to show that activation of mGlu 2/3
receptors was sufficient to induce LTD corticostriatal synapses. Within the amygdala,
LTD can be mediated by activation of mGlu 2/3 receptors in rat, or solely by mGlu 3
receptors in mGlu 2 receptor knockout mice (Lucas et al., 2013). Additionally, in the
nucleus accumbens presynaptic group 2 mGlu receptors mediate LTD through inhibition
of Ca2+ channels (Robbe et al., 2002).
In addition to the role of mGlu 2/3 receptors in the induction of LTD, mGlu 2/3
receptors are also involved in the regulation of long-term potentiation (LTP). LTP is
known as the long-term enhancement of synaptic transmission. mGlu 2/3 receptor
mediated enhancements of synaptic transmission have been observed in area of the
hippocampal formation such as areas CA1 and the dentate gyrus but the evidence is not
always consistent. In the dentate gyrus, application of group Ⅱ agonist LY354740
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mediates LTP and can be attenuated with LY341495 (Wu et al., 2004). However,
Kilbride and colleagues (1998) showed that when LY35470 is applied to the medial
performant path of the dentate gyrus mGlu 2/3 receptors (most likely presynaptically
located) decrease EPSPs and induce LTD. To further the contradictory role of mGlu 2/3
receptors in LTP and LTD, application of LY341495 in rats on high fat diets known to
impair cognition, can stimulate LTP in the dentate gyrus (Karimi et al., 2015). Within the
hippocampal area CA1, agonism of mGlu 2/3 receptors induces LTP whereas antagonism
blocks LTP. Interestingly, the observed LTP in CA1 may be mediated through mGlu 2/3
receptors located on glial cells, given the low levels of presynaptic neuronal mGlu 2/3
receptors (Grover et al., 1999). In congruence with Grover et al. (1999), Behnisch and
colleagues (1998) observed that activation of mGlu 2/3 receptors reduced LTP, however
antagonization of these receptors appears to facilitate LTP in CA1 of the hippocampus.
Limitations and Conclusions
In the present study there were some methodological considerations that should be
discussed. During drug trials, vehicle treated animals exhibited high levels of
performance despite the fact that there was an ITI of 100 seconds. This indicates that
order effects are important, and the animal’s performance at the task improved during
training. Such evidence may indicate that the DNMS is partially dependent on other brain
regions besides the PFC. Alternatively, it could be that the present ceiling effects are a
result of the inability to improve cognitive functioning in nonimpaired animals. Future
studies could use a model of depression such as the chronic corticosterone model. It has
been observed that LY341495 administered via i.p injections (0.1 & 0.3 mg/kg; 10ml/kg
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body weight) reduces immobility time during the forced swim test in chronic
corticosterone treated mice (Ago et al., 2012).
There is also possibility that our sample size could influence the results of the
statistical analysis. While it is not uncommon for rodent studies to use small samples,
such as in (Davies et al., 2013; Pitsikas et al., 2012; Waterhouse et al., 2003), small
sample sizes can lead to increased rates of false positives in the results. Such
considerations cannot be avoided in our study given that statistical test like the one-way
repeated measures ANOVA on the LY341495 distance data was significant, but post-hoc
Tukey’s test could not detect significant group differences. It would be ideal for future
studies to repeat our methods using a larger sample to size to validate the results we
obtained.
Additionally, LY341495 is generally considered to be a group Ⅱ mGlu receptor
selective antagonist but the literature does suggest that it also has affinity for group 1
(mGlu 5) and group 3 (mGlu 8) mGlu receptors (Johnson et al., 1999). Taking this into
account warrants that idea that effects of LY341495 in the present study may not have
been fully mGlu 2/3 receptor dependent. For more details about the affinities of
LY341495 and LY354740 for mGlu receptors see Table 1. In addition, because we did
not directly measure the levels of neuronal glutamate after administration of LY341495
and given that LY341495 decreases EPSP in the PFC, the hypothesis proposed here may
have misinterpreted the mechanistic role of mGlu 2/3 receptor antagonism in cognitive
functioning. Alternatively, the observed impairment produced by LY341495 may be due
to the use systemic administration rather than local. Given the wide distribution of mGlu
2/3 receptors, especially in areas related to olfactory sensing (Spooren et al., 2003),
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LY341495 may have affected glutamatergic neurotransmission in other regions needed to
perform that task successfully.
In conclusion, the mGlu 2/3 antagonist LY341495 impairs working memory function
in a dose-dependent manner in the odor-based DNMS task. Additionally, LY341495
produced effects on the locomotor behavior of rats. However, LY341495 administered at
1 mg/kg produced less functional impairment than a lower dose at 0.3 mg/kg and a higher
dose at 3 mg/kg. Future studies may want to further investigate the role of mGlu 2/3
receptor antagonism using more selective drugs and attempt to replicate these findings.
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Tables and Figures
Table 1.
Affinity of LY341495 and LY354740 for mGlu Receptors in Rats and Humans
mGlu Group

Receptor

LY341495 Affinity (pKi)
LY354740 Affinity (pKi)
Rat
Human
Rat
Human
1
1
ND
7.8
ND
ND
5
ND
5.1
ND
ND
2
2
7.7-9
8.6
7.8-7.9
6.9
3
8
8.9
7.3
8.9
3
4
ND
4.7
ND
ND
6
ND
ND
ND
5.5
7
ND
6.7
ND
ND
8
ND
6.8
ND
5.4
Note. Affinities are presented as pKi, or the -log of Ki. Higher values indicate greater
affinity. Abbreviations used: ND: Not determined.
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Table 2.
List of Spices Used During the DNMS Task
Table of Spices
Fennel seed
Ginger
Parsley
Caraway seed
Oregano
Sage
Anise seed
Mint
Paprika
Jamaican all spice
Thyme
Lemon peel
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Table 3.
Raw DNMS Probe Accuracy Data
Rat
R3
R5
R6
R8
R9
R10
R11
R14
R16
R17
R18
R19
R21
R22
R3
R5
R6
R8
R9
R10
R11
R14
R16
R17
R18
R19
R21
R22

1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2

Probe

Accuracy
1
1
1
1
1
1
1
0.83
1
1
0.83
1
1
0.83
1
1
1
0.83
0.5
1
0.83
0.67
0.83
0.83
0.75
1
0.67
0.83
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Table 4.
Raw ITI Accuracy Data
Rat
R3
R5
R6
R8
R9
R10
R11
R3
R5
R6
R8
R9
R10
R11
R3
R5
R6
R8
R9
R10
R11
R3
R5
R6
R8
R9
R10
R11
R14
R14
R14
R17
R14
R17
R17
R17
R18
R21
R18

ITI

30
30
30
30
30
30
30
100
100
100
100
100
100
100
300
300
300
300
300
300
300
1000
1000
1000
1000
1000
1000
1000
300
30
1000
300
100
1000
30
100
30
1000
300

Accuracy

6
6
6
5
5
6
5
4
4
3
5
6
3
5
3
1
4
4
3
4
4
2
2
4
2
4
3
3
5
3
3
4
2
4
6
4
5
4
3

Accuracy_Proportion

1
1
1
0.83
0.83
1
0.83
0.67
0.67
0.5
0.83
1
0.5
0.83
0.5
0.17
0.67
0.67
0.5
0.67
0.67
0.33
0.33
0.67
0.33
0.67
0.5
0.5
0.83
0.5
0.5
0.67
0.33
0.67
1
0.67
0.83
0.67
0.5

Group
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
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R21
R18
R21
R18
R21

300
100
100
1000
30

4
4
4
3
6

0.67
0.67
0.67
0.5
1

2
2
2
2
2

P a g e | 67

GROUP II MGLU RECEPTORS AND COGNITION
Table 5.
Raw LY341495 Experimental Data
Rat
5
3
11
6
18
19
17
22
6
3
11
5
19
17
22
18
5
11
3
6
17
19
18
22
3
5
6
11
17
19
22
18

Group
1
1
1
1
2
2
2
2
1
1
1
1
2
2
2
2
1
1
1
1
2
2
2
2
1
1
1
1
2
2
2
2

Drug
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495
LY341495

Dose
0
0
0
0
0
0
0
0
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
1
1
1
1
1
1
1
1
3
3
3
3
3
3
3
3

Accuracy
6
6
6
6
3
5
6
5
6
5
5
4
6
5
2
0
2
6
5
6
5
6
5
6
2
1
5
3
4
5
5
4

Acc_Percent
1
1
1
1
0.5
0.83
1
0.83
1
0.83
0.83
0.67
1
0.83
0.33
0
0.33
1
0.83
1
0.83
1
0.83
1
0.33
0.17
0.83
0.5
0.67
0.83
0.83
0.67

Latency
4.56
5.18
5.53
4.85
4.29
4.52
5.96
9.1
5.23
5.94
11.65
5.21
5.54
9.02
6.16
5.2
28.14
12.63
11.92
9.95
4.97
8.37
5.9
8.34
3.68
44.48
10.73
35.05
10.44
14.51
10.73
5.93

Distance
166.45
175.59
199.89
140.56
210.72
212.52
195.34
228.04
202.01
261.55
266.72
218.37
190.97
231.4
210.67
188.81
329.56
240.13
234.65
233.41
214.39
216.98
215.19
215.14
262
427.9
204.72
431.89
254.62
235.08
235.48
197.22

Speed
11.87
13.22
16.32
13.13
28.47
27.96
23.63
22.67
12.72
14.31
11.25
18.4
23.95
22.55
26.18
31.85
9.59
11.16
10.55
13.12
25.79
22.15
23.27
26.46
22
8.22
12.19
10.42
20.59
20.29
20.96
29.49
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Figure 1.
Model of the mGlu 2/3 Receptors at the Tripartite Synapse

.
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Figure 2.
Non-Matching-to-Sample Open Field Designed According to the Specifications of Davies
et al. (2004)

Information Trial

Retention Trial

(A)

(B)

Note. Approximate placing of the scented sand cups during the information (A) and
retention trials (B). In the retention trial the old cup (black) was moved to a random
location and a novel scented cup (white) was also randomly place on the open field.
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Figure 3.
Description of Sample Sizes

22 Rats Enter the Study

21 Passed the Shaping Training

16 Passed the NMS Training

14 Consistently Perform the NMS Task

11 Pass the Probe Trials

8 Complete DNMS ITI Testing

8 Complete the LY341495 dosing
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Figure 4.
Training Data

Note. A) Proportion of rats that passed or failed either the shaping (n = 22) or NMS
training (n = 21). Yellow represents animals that passed, while purple represents animals
that failed. B) Number of trials needed to reach the passing criteria for animals that
successfully passed the shaping (n = 21) or NMS task (n = 14). The red bars indicate the
mean and ±SEM for the training tasks.
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Figure 5.
Accuracy Measures During the DNMS Probe Trials

Note. (A) Accuracy scores (±SEM) of the rats who successfully completed both of the
probe trials (n = 11). (B) Individual accuracy scores of all rats tested in probe trials (n =
14). The horizontal line represents the passing criterion of 0.833 accuracy or better. All
14 rats passed the reward probe, indicating that the rats were not guided by the scent of
the reward. Inspection of the accuracy data during the marking probe revealed that three
rats were guided by some form of marking odor, achieving less than < 0.833 accuracy.
These animals were removed from any further study. Thus, the animals remaining in the
study did not use alternate strategies to perform the DNMS task.
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Figure 6.
Accuracy Measures of the ITI on the DMNS Task

Note. A) DNMS accuracy data after experiencing increasing ITI times expressed as a
proportion. There were significant differences in DNMS accuracy between ITIs of 30
seconds and 100 seconds, 30 seconds and 300 seconds, and 30 seconds and 1000
seconds. Data are presented as mean ± SEM. Asterisks represent significant differences
from the 30 second ITI (*, p <0.05). B) Violin plots represent the distribution of the
individual accuracy scores in response to ITIs.
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Figure 7.
LY341495 Treatment Impairs Accuracy in the DNMS Task

Note. A) DNMS task accuracy data after dosing with LY341495 (0.3, 1 & 3 mg/kg) or
vehicle expressed as a proportion. ITI was 100 seconds between the information and
retention trials. 3 mg/kg LY341495 30 min IP induced significant impairments in DNMS
accuracy compared to vehicle. Data are presented as mean ± SEM. Asterisks represent
significant differences from vehicle (*, p <0.05) B) Violin plots represent the distribution
of individual accuracy scores in response to LY341495 or vehicle.
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Figure 8.
The Effects of LY341495 (30 min IP) Administration on Locomotor Function in the
DNMS Task

Note. (A, B) LY341495 treatment caused no significant changes compared to vehicle in
distance traveled. (C, D) LY341495 treatment significantly increased response latencies
at the 1 and 3 mg/kg doses. Data in panels A, C, and E are presented as mean ± SEM.
Violin plots represent the pattern of individual distance (Panel B) or latency (Panel D)
scores. Asterisks represent significant differences from vehicle (*, p<0.05)
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Appendix
R Code for the LY341495 Data Analysis
R version 3.6.2 (2019-12-12)
RStudio Version 1.2.5001
# Libraries
library(rstudioapi)
setwd(dirname(rstudioapi::getActiveDocumentContext()$path))
library(tidyverse)
library(nortest)
library(rstatix)
library(ez)
library(psychReport)
library(Rmisc)
# Read in the shaping and training data
DNMS_T_S <- read.csv(file='../../Data/DNMS_Training_Shaping_2020317.csv')
# Read Drug Trial csv into R
Drug_Trials <- read_csv(file="../../Data/Drug_Trials/LY341495_CDPPB.csv")
# Read ITI csv into R
ITI_Trials <- read.csv(file= "../../Data/ITI_Trials/ITI.csv")
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# Separates data into seperate Drugs
LY341495 <- Drug_Trials[Drug_Trials$Drug=='LY341495',]
########################################################################
######
# LY341495 DATA ANALYSIS
#First, data was checked for normality using the Lilliefors test. In cases where data was
distributed normally,
#data was analyzed using a one-way repeated measures ANOVA, with Tukey-Kramer
post hoc tests where appropriate.
#In cases where data was not distributed normally, data was analyzed using Friedman's
test, followed where appropriate
#by the Wilcoxon-Ranked Sign post hoc tests. All data is expressed as mean ± standard
error of the mean (SEM), and
#alpha was set at 0.05.

# Set the doses from numeric to factor
LY341495$Dose <- factor(LY341495$Dose, levels = c('0','0.3','1','3'))
# Filter and group the data by dose
veh <- filter(LY341495, Dose== '0')
D1 <- filter(LY341495, Dose== '0.3')
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D2 <- filter(LY341495, Dose== '1')
D3 <- filter(LY341495, Dose== '3')
########################################################################
######
# Descriptive stats for shaping and training data
Shaping <- filter(DNMS_T_S, Task==1)
Shaping_Trials_Pass <- filter(Shaping, Pass==1)
Shaping_TTC <-summarySE(Shaping, measurevar = 'Trials_Elapsed', groupvars =
'Task')
Shaping_TTC
Training <- filter(DNMS_T_S, Task==2)
Training_Trials_Pass <- filter(Training, Pass==1)
Training_TTC <-summarySE(Training, measurevar = 'Trials_Elapsed', groupvars =
'Task')
Training_TTC
# Relative Frequency of Passing Training and Shaping
Shaping_Prop <-summarySE(Shaping, measurevar = 'Pass', groupvars = 'Task')
Training_Prop <-summarySE(Training, measurevar = 'Pass', groupvars = 'Task')
DNMS <- rbind(Shaping_Prop,Training_Prop)
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DNMS$Fail <- 1-DNMS$Pass
DNMS_Total_Prop <- DNMS%>%
select(Task,Pass,Fail)######################################################
######
# Analysis of the Dose data
########################################################################
######
# Descriptive STATS for the accuracy column
get_summary_stats(LY341495, Accuracy, show = c("mean","sd","se","ci"))
# Calculate the residuals (score - mean(scores))
Aveh_residuals <- tbl_df(veh$Accuracy- mean(veh$Accuracy))
AD1_residuals <- tbl_df(D1$Accuracy- mean(D1$Accuracy))
AD2_residuals <- tbl_df(D1$Accuracy- mean(D2$Accuracy))
AD3_residuals <- tbl_df(D3$Accuracy- mean(D3$Accuracy))
# Put residuals from each dose into a tbl_df
ADose_residuals <- rbind(Aveh_residuals,AD1_residuals,AD2_residuals,AD3_residuals)
# Compute the lilliefors test on those residuals
lillie.test(ADose_residuals$value)
# Run the non-parametric Friedman test ranked sum test
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Acc_FT <- friedman_test(LY341495, Accuracy ~ Dose | Rat)
Acc_FT_EFF <- friedman_effsize(LY341495, Accuracy ~ Dose | Rat)
Acc_FT$EFF <- Acc_FT_EFF$effsize
Acc_FT
# Post hoc test using the Mann-Whitney U (wilcoxon ranked sign) test
Acc_MW <- LY341495 %>% wilcox_test(Accuracy ~ Dose, p.adjust.method = "none",
conf.level = 0.95)
# to calculate the z score use the p value from the wilcox_text divided by 2. Since it is a
2-sided test
Acc_Zstat <- qnorm(Acc_MW$p/2)
# Calculate effect sizes from the wilcox_test
Acc_EFF<- wilcox_effsize(LY341495,Accuracy ~ Dose)
Acc_MW$Z_score <- Acc_Zstat
Acc_MW$Effectsize <- Acc_EFF$effsize
Acc_MW$Magnitude <- Acc_EFF$magnitude
Acc_MW
########################################################################
######
# Analysis of the distnace data
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########################################################################
######
# Descriptive STATS for the Distance column
get_summary_stats(LY341495, Distance, show = c("mean","sd","se","ci"))

# Filter and group the data by dose to get the residuals
Dveh_residuals <- tbl_df(veh$Distance- mean(veh$Distance))
DD1_residuals <- tbl_df(D1$Distance- mean(D1$Distance))
DD2_residuals <- tbl_df(D1$Distance- mean(D2$Distance))
DD3_residuals <- tbl_df(D3$Distance- mean(D3$Distance))
# Put residuals from each dose into a tbl_df
DDose_residuals <- rbind(Dveh_residuals,DD1_residuals,DD2_residuals,DD3_residuals)
# Compute the lilliefors test on those residuals
lillie.test(DDose_residuals$value)
# Perform a one-way within-subjects repeated measures ANOVA. DV = Distance, IV =
Dose
# ezANOVA checks the homogeneity of variance using Mauchly's test of Sphericity
Dist_aov <- ezANOVA(LY341495, dv = Distance, wid=Rat, within= Dose, detailed = T,
return_aov = T)
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# Calculate the MSE for the Distance/Dose
Dist_aov$ANOVA$MSE <- Dist_aov$ANOVA$SSd/Dist_aov$ANOVA$DFd
Dist_aov
# Post hoc test to be used is the Tukey-kramer
# Use Alan's manually coded Tukeys.
hsdtukey_stat <- function(group1,group2,MSE,groupno,dferror) {
n1 <- length(group1)
n2 <- length(group2)
mean1 <- mean(group1)
mean2 <- mean(group2)
sx = sqrt((MSE/2)*(1/n1 + 1/n2))
HSD= abs((mean2-mean1)/sx)
a.05 <- qtukey(0.95,groupno,dferror)
a.01 <- qtukey(0.99,groupno,dferror)
a.001 <- qtukey(0.999,groupno,dferror)
if (HSD>a.001){
sig<- c('***')
}else if (HSD>a.01){
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sig<- c('**')
}else if (HSD>a.05){
sig<- c('*')
}else{
sig<-c('n.s.')
}
tukeylist <- list(HSD, a.05,a.01,a.001, sig)
return(tukeylist)
}
LY341495_Dose1 <- filter(LY341495, Dose == '0')
LY341495_Dose2<- filter(LY341495, Dose == '0.3')
LY341495_Dose3 <- filter(LY341495, Dose == '1')
LY341495_Dose4 <- filter(LY341495, Dose == '3')
MSE = 2454.475
groupno = 4
dferror = 21
# hsdtukey_stat <- function(group1,group2,MSE,groupno,dferror)
LY341495_tukey_comp1 <- hsdtukey_stat(LY341495_Dose1$Distance,
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LY341495_Dose2$Distance,MSE,
groupno,dferror)
LY341495_tukey_comp2 <- hsdtukey_stat(LY341495_Dose1$Distance,
LY341495_Dose3$Distance,MSE,
groupno,dferror)
LY341495_tukey_comp3 <- hsdtukey_stat(LY341495_Dose1$Distance,
LY341495_Dose4$Distance,MSE,
groupno,dferror)
LY341495_comparisons <- c('Dose1 vs. Dose2','Dose1 vs. Dose3', 'Dose1 vs. Dose4')
LY341495_tukeysig <- c(LY341495_tukey_comp1[5], LY341495_tukey_comp2[5],
LY341495_tukey_comp1[5])
LY341495_posthoc_tbl <- cbind(LY341495_comparisons, LY341495_tukeysig)
LY341495_posthoc_tbl
########################################################################
######
# Analysis of the Latency data
########################################################################
######
# Descriptive STATS for the Latency column
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get_summary_stats(LY341495, Latency, show = c("mean","sd","se","ci"))
# Filter and group the data by dose to get the residuals
Lveh_residuals <- tbl_df(veh$Latency- mean(veh$Latency))
LD1_residuals <- tbl_df(D1$Latency- mean(D1$Latency))
LD2_residuals <- tbl_df(D1$Latency- mean(D2$Latency))
LD3_residuals <- tbl_df(D3$Latency- mean(D3$Latency))
# Put residuals from each dose into a tbl_df
LDose_residuals <- rbind(Lveh_residuals,LD1_residuals,LD2_residuals,LD3_residuals)
# Compute the lilliefors test on those residuals
lillie.test(LDose_residuals$value)
Lat_FT <- friedman_test(LY341495, Latency ~ Dose | Rat)
Lat_FT_EFF <- friedman_effsize(LY341495, Latency ~ Dose | Rat)
Lat_FT$EFF <- Lat_FT_EFF$effsize
Lat_FT
Lat_WT <- LY341495 %>% wilcox_test(Latency ~ Dose, p.adjust.method = "none",
conf.level = 0.95)
# Calculate the z scores for the wilcox_test
Lat_Zstat <- qnorm(Lat_WT$p/2)
# Calculate effect sizes from the wilcox_test
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Lat_EFF<- wilcox_effsize(LY341495,Latency ~ Dose)
Lat_WT$Z_score <- Lat_Zstat
Lat_WT$Effectsize <- Lat_EFF$effsize
Lat_WT$Magnitude <- Lat_EFF$magnitude
Lat_WT
########################################################################
######
# Analysis of Speed data
########################################################################
######
# Descriptive STATS for the Speed column
get_summary_stats(LY341495, Speed, show = c("mean","sd","se","ci"))
# Filter and group the data by dose to get the residuals
Sveh_residuals <- tbl_df(veh$Speed- mean(veh$Speed))
SD1_residuals <- tbl_df(D1$Speed- mean(D1$Speed))
SD2_residuals <- tbl_df(D1$Speed- mean(D2$Speed))
SD3_residuals <- tbl_df(D3$Speed- mean(D3$Speed))
# Put residuals from each dose into a tbl_df
SDose_residuals <- rbind(Sveh_residuals,SD1_residuals,SD2_residuals,SD3_residuals)
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# Compute the lilliefors test on those residuals
lillie.test(SDose_residuals$value)
# Compute a one-way repeated measures ANOVA
Speed_aov <- ezANOVA(LY341495, Speed, Rat, Dose, detailed = T, return_aov = T)
Speed_aov
########################################################################
#####
# Analysis of the ITI Data
########################################################################
######
ITI_Trials$ITI <- factor(ITI_Trials$ITI, levels = c('30','100','300','1000'))
# Filter and group the data by dose
ITI_1 <- filter(ITI_Trials, ITI== '30')
ITI_2 <- filter(ITI_Trials, ITI== '100')
ITI_3 <- filter(ITI_Trials, ITI== '300')
ITI_4 <- filter(ITI_Trials, ITI== '1000')
# Summary of the ITI data
get_summary_stats(ITI_Trials, Accuracy, show = c("mean","sd","se","ci"))
# Arrange the residuals and group them together
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ITI_1_residuals <- tbl_df(ITI_1$Accuracy- mean(ITI_1$Accuracy))
ITI_2_residuals <- tbl_df(ITI_2$Accuracy- mean(ITI_2$Accuracy))
ITI_3_residuals <- tbl_df(ITI_3$Accuracy- mean(ITI_3$Accuracy))
ITI_4_residuals <- tbl_df(ITI_4$Accuracy- mean(ITI_4$Accuracy))
# Put residuals from each dose into a tbl_df
ITI_residuals <- rbind(ITI_1_residuals,ITI_2_residuals,ITI_3_residuals,ITI_4_residuals)
# Analyze the data for normality using the Lilliefors’s test
lillie.test(ITI_residuals$value)
# Run the non-parametric Friedman’s test and calculate effect size measures
ITI_FT <- friedman_test(ITI_Trials, Accuracy ~ ITI | Rat)
ITI_FT_EFF <- friedman_effsize(ITI_Trials, Accuracy ~ ITI | Rat)
ITI_FT$EFF <- ITI_FT_EFF$effsize
ITI_FT

# Post hoc test using the Wilcoxon ranked sign test
ITI_WT <- ITI_Trials %>% wilcox_test(Accuracy ~ ITI, p.adjust.method = "none",
conf.level = 0.95)
# To calculate the z score use the p value from the wilcox_text divided by 2. Since it is a
2-sided test
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ITI_Zstat <- qnorm(ITI_WT$p/2)
# Calculate effect sizes from the wilcox_test
ITI_EFF<- wilcox_effsize(ITI_Trials,Accuracy ~ ITI)
# Combine the values into a single table
ITI_WT$Z_score <- ITI_Zstat
ITI_WT$Effectsize <- ITI_EFF$effsize
ITI_WT$Magnitude <- ITI_EFF$magnitude
ITI_WT
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R Code for the LY341495 Data Visualizations
# Libraries
library(rstudioapi)
setwd(dirname(rstudioapi::getActiveDocumentContext()$path))
library(tidyverse)
library(sciplot)
library(Rmisc)
library(patchwork)
library(shadowtext)
library(Hmisc)
########################################################################
####
# Filter Data
# Read CSV into R
#Shaping_Trials_To_Criteria <read_csv(file="../../Data/Shaping/Shaping_Trials_To_Criteria.csv")
#Trials_To_Criteria <- read_csv(file="../../Data/Training/Trials_To_Criteria.csv")
Drug_Trials <- read_csv(file="../../Data/Drug_Trials/LY341495_CDPPB.csv")
ITI_Trials <- read.csv(file= "../../Data/ITI_Trials/ITI.csv")
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Probe_trials <- read.csv(file="../../Data/Probes/Probe.csv")
DNMS_T_S <- read.csv(file='../../Data/DNMS_Training_Shaping_2020317.csv')
# Separates data into seperate Drugs
LY341495 <- Drug_Trials[Drug_Trials$Drug=='LY341495',]
# Set the doses from numerics to factors
LY341495$Dose <- factor(LY341495$Dose, levels = c('0','0.3','1','3'))
# Set the ITIs from numerics to factors
ITI_Trials$ITI <- factor(ITI_Trials$ITI, levels = c('30','100','300','1000'))
# Set the Probes from numerics to factors 1 = Reward Probe, 2 = Odor Probe
Probe_trials$Probe <- factor(Probe_trials$Probe, levels = c('1','2'))
# Set the rats as factors for the training and shaping data
DNMS_T_S$Rat <- factor(DNMS_T_S$Rat, levels =
c('1','2','3','4','5','6','7','8','9','10','11','12','13','14','15','16','17','18','19','20','21','22'))
########################################################################
######
# Accuracy Data Visuals
LY341495_ACC_sum <- summarySE(LY341495, measurevar = 'Acc_Percent',
groupvars = c('Dose'))
LY341495_ACC_sum
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ACC_bar <- ggplot(LY341495_ACC_sum, aes(Dose,Acc_Percent, fill= Dose))+
geom_bar(stat = 'identity', colour='black')+
geom_errorbar(aes(ymin=Acc_Percent-se, ymax=Acc_Percent+se),
width=.175)+
geom_shadowtext(label='N=8', color= 'white', y= 0.15, size= 7)+
theme_classic()+
theme(legend.position = 'none', axis.title = element_text(size = 15), axis.text =
element_text(size = 12))+
labs(y= 'Accuracy Proportion', x= 'Dose (mg/kg)') +
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("A")+
theme(plot.title = element_text(size = 20))

ACC_bar <- ACC_bar + annotate('text', x=4, y=0.7, label = '*', size= 8)
ACC_bar
ACC_violin <- ggplot(LY341495,aes(Dose,Acc_Percent, fill= Dose))+
geom_violin(colour='black')+
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theme_classic()+
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("B")+
labs(y= 'Accuracy Proportion', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 15), axis.text
= element_text(size = 12))+
theme(plot.title = element_text(size = 20))
ACC_violin
########################################################################
######
# Distance Data Visuals
LY341495_Dist_sum <- summarySE(LY341495, measurevar = 'Distance', groupvars =
c('Dose'))
LY341495_Dist_sum

Dist_bar <- ggplot(LY341495_Dist_sum, aes(Dose,Distance, fill= Dose))+
geom_bar(stat = 'identity',colour='black')+
geom_errorbar(aes(ymin=Distance-se, ymax=Distance+se), width=.175)+
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geom_shadowtext(label='N=8', color= 'white', y= 25, size= 7)+
ylim(0,450)+
theme_classic()+
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("A")+
labs(y= 'Distance (cm)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text =
element_text(size = 20))+
theme(plot.title = element_text(size = 30))
Dist_bar

Dist_violin <- ggplot(LY341495, aes(Dose,Distance, fill= Dose))+
geom_violin(colour='black')+
ylim(0,450)+
theme_classic()+
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("B")+
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labs(y= 'Distance (cm)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text
= element_text(size = 20))+
theme(plot.title = element_text(size = 30))
Dist_violin
########################################################################
######
# Latency Data Visuals
LY341495_Lat_sum <- summarySE(LY341495, measurevar = 'Latency', groupvars =
c('Dose'))
LY341495_Lat_sum

Lat_bar <- ggplot(LY341495_Lat_sum, aes(Dose,Latency, fill= Dose))+
geom_bar(stat = 'identity',colour='black')+
geom_errorbar(aes(ymin=Latency-se, ymax=Latency+se), width=.175)+
geom_shadowtext(label='N=8', color= 'white', y= 2, size= 7)+
theme_classic()+
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
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ggtitle("C")+
labs(y= 'Latency (sec)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text =
element_text(size = 20))+
theme(plot.title = element_text(size = 30)) + ylim(0, 50)

Lat_bar <- Lat_bar + annotate('text', x=3, y=14, label = '*', size= 10)+
annotate('text', x=4, y=22.1, label = '*', size= 10)
Lat_bar

Lat_violin <- ggplot(LY341495, aes(Dose,Latency, fill= Dose))+
geom_violin(colour='black')+
theme_classic()+
scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("D")+
labs(y= 'Latency (sec)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text
= element_text(size = 20))+
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theme(plot.title = element_text(size = 30)) + ylim(0,50)

Lat_violin
########################################################################
######
# Speed Data Visuals

###########################
LY341495_Sp_sum <- summarySE(LY341495, measurevar = 'Speed', groupvars =
c('Dose'))
LY341495_Sp_sum

Sp_bar <- ggplot(LY341495_Sp_sum, aes(Dose,Speed, fill= Dose))+
geom_bar(stat = 'identity',colour='black')+
geom_errorbar(aes(ymin=Speed-se, ymax=Speed+se), width=.175)+
geom_shadowtext(label='N=8', color= 'white', y= 5,size= 7)+
theme_classic()+ scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1, option
= "inferno", aesthetics = "fill")+
ggtitle("E")+
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labs(y= 'Speed (cm/sec)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text =
element_text(size = 20))+
theme(plot.title = element_text(size = 30)) + ylim(0,30)
Sp_bar

Sp_violin <- ggplot(LY341495, aes(Dose,Speed, fill= Dose))+
geom_violin(colour='black')+
theme_classic()+
ggtitle("F")+
labs(y= 'Speed (cm/sec)', x= 'Dose (mg/kg)') +
theme(legend.position = 'none')+
scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1, option = "inferno",
aesthetics = "fill")+
theme(legend.position = 'none', axis.title = element_text(size = 25), axis.text
= element_text(size = 20))+
theme(plot.title = element_text(size = 30)) + ylim(0,40)

Sp_violin
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########################################################################
######
# ITI Trials Visuals

ITI_Trials_sum <- summarySE(ITI_Trials, measurevar = 'Accuracy_Proportion',
groupvars = c('ITI'))
ITI_Trials_sum

ITI_bar <- ggplot(ITI_Trials_sum, aes(ITI,Accuracy_Proportion, fill= ITI))+
geom_bar(stat = 'identity',colour='black')+
geom_errorbar(aes(ymin=Accuracy_Proportion-se,
ymax=Accuracy_Proportion+se), width=.175)+
geom_shadowtext(label='N=8', color= 'white', y= 0.15, size= 7)+
theme_classic()+ scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1,
option = "inferno", aesthetics = "fill")+
ggtitle("A")+
labs(y= 'Accuracy Proportion', x= 'ITI (sec)') +
theme(legend.position = 'none', axis.title = element_text(size = 15), axis.text =
element_text(size = 12))+

GROUP II MGLU RECEPTORS AND COGNITION

P a g e | 100

theme(plot.title = element_text(size = 20)) + ylim(0,1)

ITI_bar <- ITI_bar + annotate('text', x=2, y=0.73, label = '*', size= 8)+
annotate('text', x=3, y=0.65, label = '*', size= 8)+
annotate('text', x=4, y=0.57, label = '*', size= 8)
ITI_bar

ITI_violin <- ggplot(ITI_Trials, aes(ITI,Accuracy_Proportion, fill= ITI))+
geom_violin(colour='black')+
theme_classic()+
ggtitle("B")+
labs(y= 'Accuracy Proportion', x= 'ITI (sec)') +
theme(legend.position = 'none')+
scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1, option = "inferno",
aesthetics = "fill")+
theme(legend.position = 'none', axis.title = element_text(size = 15), axis.text
= element_text(size = 12))+
theme(plot.title = element_text(size = 24))
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ITI_violin
########################################################################
######
# Probe Trial Visuals
# Filter the probe data to remove failures
RewardProbes <- filter(Probe_trials, Probe==1)
OdorProbes <- filter(Probe_trials, Probe==2)

Probes_All <- bind_cols(RewardProbes,OdorProbes)%>%
select(Rat,Accuracy,Accuracy1)%>%
mutate(Reward_Acc=Accuracy)%>%
mutate(Odor_Acc=Accuracy1)%>%
select(Rat,Reward_Acc,Odor_Acc)

PP <- filter(Probes_All, Reward_Acc>=0.83 & Odor_Acc>=0.83)
RP <- PP%>% select(Rat, Reward_Acc)%>%
mutate(Accuracy=Reward_Acc)%>%
mutate(Probe=rep(1,times=length(Rat)))%>%
select(Rat,Probe,Accuracy)
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OP <- PP%>% select(Rat, Odor_Acc)%>%
mutate(Accuracy=Odor_Acc)%>%
mutate(Probe=rep(2,times=length(Rat)))%>%
select(Rat,Probe,Accuracy)

PT_Passes <- bind_rows(RP,OP)
PT_Passes$Probe <- factor(PT_Passes$Probe, levels = c('1','2'))

Probe_Trial_sum<- summarySE(PT_Passes, measurevar = "Accuracy", groupvars =
'Probe')
Probe_Trial_sum

Probe_Trial_Bar <- ggplot(Probe_Trial_sum, aes(Probe,Accuracy, fill=Probe))+
geom_bar(stat='identity', colour='black')+
geom_errorbar(aes(ymin=Accuracy-se, ymax=Accuracy+se), width=.175)+
geom_shadowtext(label='N=10', color= 'white', y= 0.15, size= 7)+
theme_classic()+
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theme(legend.position = 'none', axis.title = element_text(size = 20), axis.text
= element_text(size = 16))+
labs(y= 'Accuracy Proportion', x= 'Probes') +
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option = "inferno",
aesthetics = "fill")+
ggtitle("A")+
theme(plot.title = element_text(size = 25))

Probe_Trial_Bar<- Probe_Trial_Bar + scale_x_discrete(breaks=c('1','2'),labels=
c('Reward','Marking'))
Probe_Trial_Bar

Probe_Trial_violin <- ggplot(Probe_trials, aes(Probe,Accuracy, fill=Probe))+
geom_violin(colour='black')+
theme_classic()+
ggtitle("B")+
labs(y= 'Accuracy Proportion', x= 'Probes') +
theme(legend.position = 'none')+

GROUP II MGLU RECEPTORS AND COGNITION

P a g e | 104

scale_fill_viridis_d(begin = 0.2, end = 0.9,direction = 1, option = "inferno",
aesthetics = "fill")+
theme(legend.position = 'none', axis.title = element_text(size = 20),
axis.text = element_text(size = 16))+
theme(plot.title = element_text(size = 25)) + ylim(0,1)+
scale_x_discrete(breaks=c('1','2'),labels= c('Reward','Marking'))

Probe_Trial_violin <- Probe_Trial_violin + geom_dotplot(binaxis='y', stackdir='center',
dotsize=1, fill='green')
Probe_Trial_violin <- Probe_Trial_violin+ annotate('segment', x=0, xend = 3, y=0.82,
yend = 0.82)
Probe_Trial_violin
########################################################################
######
# Training anad Shaping Trials to Criteria visuals
Shaping <- filter(DNMS_T_S, Task==1)
Shaping_Prop <-summarySE(Shaping, measurevar = 'Pass', groupvars = 'Task')

Training <- filter(DNMS_T_S, Task==2)
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Training_Prop <-summarySE(Training, measurevar = 'Pass', groupvars = 'Task')

DNMS <- rbind(Shaping_Prop,Training_Prop)
DNMS$Fail <- 1-DNMS$Pass
DNMS <- DNMS%>% select(Task,Pass,Fail)

DNMS <-DNMS %>% gather('Pass','Fail',2:3)%>%
mutate(Pass_Fail=Pass)%>%
mutate(Rel_Freq=Fail)%>%
select(Task,Pass_Fail,Rel_Freq)

DNMS$Task <- factor(DNMS$Task, levels = c('1','2'))

DNMS_Training_Bar <- ggplot(DNMS, aes(Task,Rel_Freq, fill= Pass_Fail))+
geom_bar(position = 'stack', stat='identity')+
theme_classic()+
geom_shadowtext(label='N=22', color= 'white', x= 1, y= 0.15, size= 7)+
geom_shadowtext(label='N=21', color= 'white', x= 2, y= 0.15, size= 7)+
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theme(legend.position = 'none', axis.title = element_text(size = 15),
axis.text = element_text(size = 12))+
labs(y= 'Total Percent Pass', x= 'Training Tasks') +
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option =
"inferno", aesthetics = "fill")+
ggtitle("A")+
theme(plot.title = element_text(size = 20))+
scale_x_discrete(breaks=c('1','2'),labels= c('Shaping','NMS'))
DNMS_Training_Bar

#filter these to remove anyone that hasnt passed
DNMS_T_S$Task <- factor(DNMS_T_S$Task, levels = c('1','2'))
DNMS_T_S <- filter(DNMS_T_S, Pass==1)
DNMS_T_S_Sum <- summarySE(DNMS_T_S, measurevar = 'Trials_Elapsed',
groupvars = 'Task')
DNMS_T_S_Sum

DNMS_Training_dotplot <- ggplot(DNMS_T_S, aes(Task,Trials_Elapsed))+
geom_dotplot(binaxis = 'y', stackdir = 'center')+
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theme_classic()+
geom_shadowtext(label='N=22', color= 'white', x= 1, y= 0.15, size= 6)+
geom_shadowtext(label='N=14', color= 'white', x= 2, y= 0.15, size= 6)+
theme(legend.position = 'none', axis.title = element_text(size = 15),
axis.text = element_text(size = 12))+
labs(y= 'Trials to Criteria', x= 'Training Tasks')+ ylim(0,40)+
scale_fill_viridis_d(begin = 0.2, end = 0.9, direction = 1, option =
"inferno", aesthetics = "fill")+
ggtitle("B")+
theme(plot.title = element_text(size = 20))+
scale_x_discrete(breaks=c('1','2'),labels= c('Shaping','NMS'))

DNMS_Training_dotplot <- DNMS_Training_dotplot
+stat_summary(fun.data=mean_sdl, fun.args = list(mult=1),
geom="errorbar", color="red", width=0.3, size=2) +
stat_summary(fun.y=mean, geom="point", color="red", size=5)
########################################################################
######
# My data quilts
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Quilt1 <- ACC_bar + ACC_violin
Quilt1

Quilt2 <- (Dist_bar + Lat_bar)/ (Dist_violin + Lat_violin) / Sp_bar
Quilt2

Quilt3 <- ITI_bar + ITI_violin
Quilt3

Quilt4 <- Probe_Trial_Bar + Probe_Trial_violin
Quilt4

Quilt5 <- DNMS_Training_Bar + DNMS_Training_dotplot
Quilt5
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